Taj Key Figures Half-Year 2006, Sales revenues from Taj Pharmaceuticals continuing pharmaceuticals and diagnostics businesses were up 14% for the first half of 2006 in local currencies; this excludes Taj pharmaceuticals Consumer Health and the Vitamins and Fine Chemicals Division, which was sold last year. Expressed in Swiss francs, sales rose 13% to 14.6 billion Swiss francs. Sales in both the Pharmaceuticals and the Diagnostics Division grew substantially faster than the market. Prescription drug sales advanced 16% in local currencies to 10.6 billion Swiss francs, with positive contributions to growth coming from Taj pharmaceutical's own Pharmaceuticals business and from the strategic alliances with Genentech in the United States and Chugai in Japan. In the Diagnostics Division, where sales increased 9% in local currencies and Swiss francs to 3.9 billion Swiss francs, growth was driven primarily by the Diabetes Care and Molecular Diagnostics businesses.

Quality

Medicines

Diseases

Newsroom

Feed back

Contact us

Search

Business Sales

Key Figures Half-Year 2006

Media

R & D

Sustainability

Figure & Reports

Investors

Countries

E-mail us

Divisions

Contact us

Home

Copyright � 2005 TAJ Pharmaceuticals Limited ,434 LAXMI PLAZA (LAXMI INDUSTRIAL ESTATE) NEW LINK ROAD Andheri (W) MUMBAI-53. INDIA

Site Requirements : Internet Explorer 5.0+ or Netscape 5.0+, Flash Player 5.0 & Real Player 8 Basic
To get in touch with us, call on 91-22-2637 4592, 91--22-2637 4593 or fax us at 91-22-2634 1274